Business
Multi-partner grant awarded
Multi-partner grant awarded.
About this update from Genedrive Plc
[{"type":"text","content":"\n\ngenedrive plc\n(\"genedrive\" or the \"Company\")\n \nMulti-partner grant awarded for the validation of Genedrive® CYP2C19 ID Kit in time critical NHS settings\n \nManchester NHS Industry partnership programme for rapid genomic test implementation\ngenedrive plc (the \"Company\"), the point of care molecular diagnostics company, today announces its participation in a multi-partner grant award (\"DEVOTE\") from Innovate UK and the UK government Innovation Accelerator programme with funding expected to be made available to further the validation and implementation of the new Genedrive® CYP2C19 ID Kit pharmacogenetic test in a time critical clinical setting.\nThe Development and Validation of Technology for Time Critical Genomic Testing (DEVOTE) grant will provide acute care patient access and supporting infrastructure for the Company to assess the real world clinical performance of time-critical clinical tests in an NHS settings. The programme, led by the University of Manchester (UoM), builds on the model of the previous successful UoM/genedrive partnership with the PALOH programme, which supported the development and evaluation of the Genedrive® MT-RNR1 ID Kit which has recently received a recommendation from NICE.\nDEVOTE pulls together health economists, clinicians, informaticians, and researchers to quickly access new technologies, and provide feedback in an iterative fashion. Genedrive's CYP2C19 ID Kit is one of three exemplar projects to be included in the programme which is expected to be funded through the Innovate grant, in-kind contributions, and other aligned funding. In the main, funding is expected to go directly to the UoM and its NHS partners to set up and coordinate the three projects, the total amount of funding to be made available under the programme will be determined in due course.\nDEVOTE will focus on ischaemic stroke patients in acute care who are targeted to be prescribed Clopidogrel to prevent further clot formation. Clopidogrel is less efficacious in individuals with certain genetic CYP2C19 variants because they do not metabolize Clopidogrel effectively. Genedrive's CYP2C19 ID Kit is being developed to provide guidance at the point of care on which patients will respond fully to Clopidogrel. Patients with gene variants that result in reduced or loss of fun...